Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marjan A Versnel

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
Plos One|October 19, 2018
Type 1 interferon-inducible gene expression in QuantiFERON Gold TB-positive uveitis: A tool to stratify a high versus low risk of active tuberculosis?Rina La Distia Nora, Ratna Sitompul, Marleen Bakker, et al.
RMD Open|August 2, 2023
Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren's syndrome that show potential to predict and monitor clinical responseSafae Hamkour, Eefje Hm van der Heijden, Ana P Lopes, et al.
Annals of the Rheumatic Diseases|September 16, 2015
The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesisZana Brkic, Lenny van Bon, Marta Cossu, et al.
Annals of the Rheumatic Diseases|March 1, 2023
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practiceJavier Rodríguez-Carrio, Agata Burska, Philip G Conaghan, et al.
Rheumatology (Oxford, England)|February 24, 2018
Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activityIris L A Bodewes, Shereen Al-Ali, Cornelia G van Helden-Meeuwsen, et al.
Arthritis Research & Therapy|March 7, 2014
T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?Zana Brkic, Odilia B J Corneth, Cornelia G van Helden-Meeuwsen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 12, 2016
Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's SyndromeNaomi I Maria, Cornelia G van Helden-Meeuwsen, Zana Brkic, et al.
Rheumatology (Oxford, England)|January 13, 2022
Hyperresponsive cytosolic DNA-sensing pathway in monocytes from primary Sjögren's syndromeErika Huijser, Iris L A Bodewes, Mirthe S Lourens, et al.
Rheumatology (Oxford, England)|February 10, 2022
Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal studyM Javad Wahadat, Dieneke Schonenberg-Meinema, Cornelia G van Helden-Meeuwsen, et al.
Journal of Autoimmunity|May 7, 2025
Microbial dysbiosis fuels STING-driven autoinflammation through cyclic dinucleotidesTakayuki Shibahara, Burcu Temizoz, Shiori Egashira, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Plos One|October 19, 2018
Type 1 interferon-inducible gene expression in QuantiFERON Gold TB-positive uveitis: A tool to stratify a high versus low risk of active tuberculosis?Rina La Distia Nora, Ratna Sitompul, Marleen Bakker, et al.
RMD Open|August 2, 2023
Leflunomide/hydroxychloroquine combination therapy targets type I IFN-associated proteins in patients with Sjögren's syndrome that show potential to predict and monitor clinical responseSafae Hamkour, Eefje Hm van der Heijden, Ana P Lopes, et al.
Annals of the Rheumatic Diseases|September 16, 2015
The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesisZana Brkic, Lenny van Bon, Marta Cossu, et al.
Annals of the Rheumatic Diseases|March 1, 2023
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practiceJavier Rodríguez-Carrio, Agata Burska, Philip G Conaghan, et al.
Rheumatology (Oxford, England)|February 24, 2018
Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activityIris L A Bodewes, Shereen Al-Ali, Cornelia G van Helden-Meeuwsen, et al.
Arthritis Research & Therapy|March 7, 2014
T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?Zana Brkic, Odilia B J Corneth, Cornelia G van Helden-Meeuwsen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 12, 2016
Association of Increased Treg Cell Levels With Elevated Indoleamine 2,3-Dioxygenase Activity and an Imbalanced Kynurenine Pathway in Interferon-Positive Primary Sjögren's SyndromeNaomi I Maria, Cornelia G van Helden-Meeuwsen, Zana Brkic, et al.
Rheumatology (Oxford, England)|January 13, 2022
Hyperresponsive cytosolic DNA-sensing pathway in monocytes from primary Sjögren's syndromeErika Huijser, Iris L A Bodewes, Mirthe S Lourens, et al.
Rheumatology (Oxford, England)|February 10, 2022
Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicentre longitudinal studyM Javad Wahadat, Dieneke Schonenberg-Meinema, Cornelia G van Helden-Meeuwsen, et al.
Journal of Autoimmunity|May 7, 2025
Microbial dysbiosis fuels STING-driven autoinflammation through cyclic dinucleotidesTakayuki Shibahara, Burcu Temizoz, Shiori Egashira, et al.
Pageof 8